Skip to content

Piramal Pharma Rights Issue 2023 Details

Piramal Pharma

We provide instant Stock Market updates on our Telegram Channel : Follow Now

Established in 2020, Piramal Pharma Limited (NSE: PPLPHARMA) a flagship company of the Piramal Group offers pharmaceutical products and services across a domestic and global distribution network. The company has 15 international manufacturing facilities and a global distribution network in over 100 countries. On 18th July 2023, Piramal Pharma gets approval from the Securities and Exchange Board of India (SEBI) for a rights issue, totaling up to Rs 1,050 crore.

[stock_market_widget type=”card” template=”extended” color=”#000000″ assets=”PPLPHARMA.NS” display_currency_symbol=”true” api=”yf”]

 Rights Issue Open:Aug 8, 2023
 Rights Issue Close:Aug 17, 2023
 Rights Record Date:Aug 2, 2023
 Deemed Date of Allotment Aug 23, 2023
 Renunciation of Rights EntitlementsAug 10, 2023

Piramal Pharma Rights Issue 2023 Offer Details

 Rights Issue Size:₹1,050.00 Crores
 Issue Price: ₹81 per share
 Face Value: ₹10 per share
 Listing on: BSE, NSE
 Entitlement Ratio:  5 Rights Equity Shares for every 46 Equity Shares
 Equity: 12.96 Crores Equity Share
 Letter of Offer: Click Here
 Application Form: Click Here

Terms of Payment

The full amount of Rs 81 per share has to be paid at the time of Application.

Piramal Pharma Rights Entitlement Ratio

 5 Rights Equity Shares for every 46 Equity Shares holding on the record date of 2nd August 2023

Company Address:

Piramal Pharma Limited
Ground Floor, Piramal Ananta,
Agastya Corporate Park, Kamani Junction,
LBS Marg, Kurla, Mumbai 400 070

Phone: +91 22 3802 3000
Email: [email protected]


Above Stocks Team

Share this post on social

Leave a Reply

Your email address will not be published. Required fields are marked *

About us

Above Stocks is your trusted source for comprehensive stock market insights, news, and expert recommendations. Empowering investors with knowledge and confidence for financial success.

Disclaimer: Stock Market investments are subject to market risks. All the information provided on our Portal is for education purposes only. Kindly consult your Financial Advisor before taking any decision.